Cardiovascular gene therapy: current status and therapeutic potential

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Regenerative Medicine

Background:

• Gene therapy is being explored for cardiovascular diseases like coronary artery disease and peripheral vascular disease.
• Preclinical studies demonstrated potential using genes like vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) for ischemic conditions.
• Genes such as TIMPs have shown success in animal models for preventing vein graft failure and in-stent restenosis by targeting neointimal hyperplasia.

Purpose of the Study:

• To review the current status of cardiovascular gene therapy.
• To assess the potential of gene therapy as a viable treatment option for cardiovascular diseases.
• To identify key parameters for future clinical trials.

Main Methods:

• Review of preclinical studies and early-phase clinical trials (Phase 1 and Phase 2) in cardiovascular gene therapy.
• Analysis of gene targets, vectors, and delivery systems used in cardiovascular gene therapy research.
• Evaluation of safety and efficacy data from completed clinical trials.

Main Results:

• Phase 1 trials indicated safety and some efficacy for cardiovascular gene therapies, with few adverse effects.
• Phase 2 trials, including placebo groups, failed to consistently confirm the efficacy suggested by earlier studies.
• Successful prevention of vein graft failure and in-stent restenosis in animal models using genes like VEGF, FGF, and TIMPs.

Conclusions:

• Cardiovascular gene therapy holds potential but faces challenges in translating preclinical promise to clinical efficacy.
• Future gene therapy trials require optimization of vectors, gene targets, and delivery systems for specific cardiovascular conditions.
• Further research and carefully designed clinical trials are essential to establish gene therapy as an effective cardiovascular treatment.